Safety of intrathecal treatment with nusinersen therapy with spinal muscular atrophy SMA Typ 2/3
New study from University Essen shows great results
University Essen treated a total of 28 adult SMA patients (9 patients with SMA type 2 and 19 patients with SMA type 3) aged between 18–61 years with nusinersen. The mean Revised Upper Limb Module (RULM) score at baseline in SMA type 2 and SMA type 3 patients was 9.9 ± 4.6 and 29.5 ± 8.5, respectively.
The data demonstrate the feasibility and tolerability of intrathecal treatment with nusinersen in adults with SMA type 2 and type 3, but this is a logistically challenging, particularly in patients with SMA type 2 and in patients with spondylodesis.
för barn med särskilda behov
- Convaid | R82 develops and manufactures pediatric products typically prescribed for children with mild to moderate involvement of the following conditions:
- Autism Spectrum Disorder, Cerebral Palsy, Down Syndrome, Duchenne Muscular Dystrophy, Spinal Muscular Atrophy, Spina Bifida, Osteogenesis Imperfecta, Traumatic Brain Injury, Spinal Cord Injury, Cystic Fibrosis, Mitochondrial Disease, Metabolic Diseases, and Sensory Processing Disorders, among others.
TREAT-NMD announce the first SMA Expert Masterclass in Rome/Italy
It will take place Monday 19th and Tuesday the 20th of November in central Rome, Italy.
Leading experts will deliver presentations and interactive workshops to disseminate information on:
Latest updates on standards of care.
Current treatment guidelines and available therapy options with review of market access options in Europe.
You are interest, click here